Area of research
Pulmonary and Respiratory Medicine · Cardiology and Cardiovascular Medicine
Research interest
Research focused on Pulmonary hypertension and Cardiology, with related work in Riociguat, Cluster (spacecraft), Interquartile range. Notable publications include 'Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model', 'Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: Results from the COMPERA registry', and 'COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension'.
Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death
Treatment With Oral or Inhaled Treprostinil in Patients With Pulmonary Arterial Hypertension and Cardiovascular Comorbidities
Defining the clinical validity of genes reported to cause pulmonary arterial hypertension
Treatment strategies and survival of patients with connective tissue disease and pulmonary arterial hypertension: a COMPERA analysis
Phenotyping of idiopathic pulmonary arterial hypertension: a registry analysis
Risk stratification and response to therapy in patients with pulmonary arterial hypertension and comorbidities: A COMPERA analysis
Clinical significance of pulmonary hypertension in interstitial lung disease: A consensus statement from the Pulmonary Vascular Research Institute's innovative drug development initiative—Group 3 pulmonary hypertension
ISHLT consensus statement: Perioperative management of patients with pulmonary hypertension and right heart failure undergoing surgery
Sex-specific effects of daily tadalafil on diabetic heart kinetics in RECOGITO, a randomized, double-blind, placebo-controlled trial
Imaging the right atrium in pulmonary hypertension: A systematic review and meta-analysis
Prognostic value of improvement endpoints in pulmonary arterial hypertension trials: A COMPERA analysis
Incremental value of cardiopulmonary exercise testing in intermediate-risk pulmonary arterial hypertension
COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension
Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial
Temporal trends in pulmonary arterial hypertension: results from the COMPERA registry
Pulmonary Hypertension in Patients With COPD
Aggressive Afterload Lowering to Improve the Right Ventricle: A New Target for Medical Therapy in Pulmonary Arterial Hypertension?
Idiopathic pulmonary arterial hypertension phenotypes determined by cluster analysis from the COMPERA registry
Clinical implications of idiopathic pulmonary arterial hypertension phenotypes defined by cluster analysis
Pulmonary Hypertension in Adults with Congenital Heart Disease: Real-World Data from the International COMPERA-CHD Registry
Sex-Specific Effects of Daily Tadalafil on Contraction Kinetics of the Diabetic Heart. The RECOGITO Randomized, Double-Blind, Placebo-Controlled Trial
Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model
RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors
Pre-Capillary, Combined, and Post-Capillary Pulmonary Hypertension
Long-term safety and efficacy of imatinib in pulmonary arterial hypertension
Pulmonary Hypertension in Patients with Chronic Fibrosing Idiopathic Interstitial Pneumonias
Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: Results from the COMPERA registry
Pregnancy outcomes in pulmonary arterial hypertension in the modern management era
Outcomes of noncardiac, nonobstetric surgery in patients with PAH: an international prospective survey